Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and
Blood After Oral Administration of Medical Cannabis With
Respect to its Effect on Driving Abilities

J 2022

Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities

TROJAN, Vaclav, Leoš LANDA, Radovan HRIB, Jan JUŘICA, Jitka RYCHLÍČKOVÁ et. al.

Základní údaje

Originální název

Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities

Autoři

TROJAN, Vaclav (203 Česká republika, garant), Leoš LANDA (203 Česká republika, domácí), Radovan HRIB (203 Česká republika), Jan JUŘICA (203 Česká republika, domácí), Jitka RYCHLÍČKOVÁ (203 Česká republika, domácí), Vaclav ZVONICEK (203 Česká republika), Lenka HALAMKOVA (203 Česká republika), Jan HALAMEK (203 Česká republika), Regina DEMLOVÁ (203 Česká republika, domácí), Silvie BĚLAŠKOVÁ (203 Česká republika, domácí) a Jiri SLIVA (203 Česká republika)

Vydání

Physiological Research, Praha, Akademie Ved Ceske Republiky, 2022, 0862-8408

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.100

Kód RIV

RIV/00216224:14110/22:00127231

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.33549/physiolres.934907

UT WoS

000892128700007

Klíčová slova česky

Delta-9-tetrahydrocannabinol; Cannabis; Driving abilities; Chronic pain treatment

Klíčová slova anglicky

Delta-9-tetrahydrocannabinol; Cannabis; Driving abilities; Chronic pain treatment

Štítky

14110516, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 4. 2023 13:53, Mgr. Tereza Miškechová

Anotace

V originále

Summary Medical cannabis has recently been legalized in many countries, and it is currently prescribed with increasing frequency, particularly for treatment of chronic pain resistant to conventional therapy. The psychoactive substance delta-9-tetrahydrocannabinol (THC) contained in cannabis may affect driving abilities. Therefore, the aims of this study (open-label, monocentric, nonrandomized) were to evaluate blood and saliva concentrations of THC after oral administration of medical cannabis and to assess the time needed for THC levels to decline below a value ensuring legal driving. The study involved 20 patients with documented chronic pain using long-term medical cannabis therapy. They were divided into two groups and treated with two different doses of cannabis in the form of gelatin capsules (62.5 mg or 125 mg). In all patients, the amount of THC was assessed in saliva and in blood at pre-defined time intervals before and after administration. THC levels in saliva were detected at zero in all subjects following administration of both doses at all-time intervals after administration. Assessment of THC levels in blood, however, showed positive findings in one subject 9 h after administration of the lower dose and in one patient who had been given a higher dose 7 h after administration. Our finding suggested that for an unaffected ability to drive, at least 9-10 h should elapse from the last cannabis use.

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

TROJAN, Vaclav, Leoš LANDA, Radovan HRIB, Jan JUŘICA, Jitka RYCHLÍČKOVÁ, Vaclav ZVONICEK, Lenka HALAMKOVA, Jan HALAMEK, Regina DEMLOVÁ, Silvie BĚLAŠKOVÁ a Jiri SLIVA. Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities. Physiological Research. Praha: Akademie Ved Ceske Republiky, 2022, roč. 71, č. 5, s. 703-712. ISSN 0862-8408. Dostupné z: https://dx.doi.org/10.33549/physiolres.934907.

@article{2233719,
   author = {Trojan, Vaclav and Landa, Leoš and Hrib, Radovan and Juřica, Jan and Rychlíčková, Jitka and Zvonicek, Vaclav and Halamkova, Lenka and Halamek, Jan and Demlová, Regina and Bělašková, Silvie and Sliva, Jiri},
   article_location = {Praha},
   article_number = {5},
   doi = {http://dx.doi.org/10.33549/physiolres.934907},
   keywords = {Delta-9-tetrahydrocannabinol; Cannabis; Driving abilities; Chronic pain treatment},
   language = {eng},
   issn = {0862-8408},
   journal = {Physiological Research},
   title = {Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities},
   url = {https://www.biomed.cas.cz/physiolres/pdf/2022/71_703.pdf},
   volume = {71},
   year = {2022}
}

TY  - JOUR
ID  - 2233719
AU  - Trojan, Vaclav - Landa, Leoš - Hrib, Radovan - Juřica, Jan - Rychlíčková, Jitka - Zvonicek, Vaclav - Halamkova, Lenka - Halamek, Jan - Demlová, Regina - Bělašková, Silvie - Sliva, Jiri
PY  - 2022
TI  - Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities
JF  - Physiological Research
VL  - 71
IS  - 5
SP  - 703-712
EP  - 703-712
PB  - Akademie Ved Ceske Republiky
SN  - 08628408
KW  - Delta-9-tetrahydrocannabinol
KW  - Cannabis
KW  - Driving abilities
KW  - Chronic pain treatment
UR  - https://www.biomed.cas.cz/physiolres/pdf/2022/71_703.pdf
N2  - Summary Medical cannabis has recently been legalized in many countries, and it is currently prescribed with increasing frequency, particularly for treatment of chronic pain resistant to conventional therapy. The psychoactive substance delta-9-tetrahydrocannabinol (THC) contained in cannabis may affect driving abilities. Therefore, the aims of this study (open-label, monocentric, nonrandomized) were to evaluate blood and saliva concentrations of THC after oral administration of medical cannabis and to assess the time needed for THC levels to decline below a value ensuring legal driving. The study involved 20 patients with documented chronic pain using long-term medical cannabis therapy. They were divided into two groups and treated with two different doses of cannabis in the form of gelatin capsules (62.5 mg or 125 mg). In all patients, the amount of THC was assessed in saliva and in blood at pre-defined time intervals before and after administration. THC levels in saliva were detected at zero in all subjects following administration of both doses at all-time intervals after administration. Assessment of THC levels in blood, however, showed positive findings in one subject 9 h after administration of the lower dose and in one patient who had been given a higher dose 7 h after administration. Our finding suggested that for an unaffected ability to drive, at least 9-10 h should elapse from the last cannabis use.
ER  -

TROJAN, Vaclav, Leoš LANDA, Radovan HRIB, Jan JUŘICA, Jitka RYCHLÍČKOVÁ, Vaclav ZVONICEK, Lenka HALAMKOVA, Jan HALAMEK, Regina DEMLOVÁ, Silvie BĚLAŠKOVÁ a Jiri SLIVA. Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities. \textit{Physiological Research}. Praha: Akademie Ved Ceske Republiky, 2022, roč.~71, č.~5, s.~703-712. ISSN~0862-8408. Dostupné z: https://dx.doi.org/10.33549/physiolres.934907.

Podrobný výpis o publikaci